Clinical Trials Search
Clinical Trial 19207
Study Type: Treatment
Phase of Study: Phase II
- Jonathan Strosberg
Phase II Study of Pembrolizumab in Advanced Poorly-Differentiated and/or High-Grade Neuroendocrine Tumors/Carcinomas
The purpose of this study is to: Assess overall radiographic response rate (ORR); Assess progression-free survival (PFS); Test the safety and tolerability of Pembrolizumab.
Objective: To assess the overall radiographic response rate (ORR) associated with pembrolizumab in patients with advanced, progressive high-grade and/or poorly differentiated extrapulmonary neuroendocrine cancers. Objective: To assess progression-free survival (PFS) in this population based on RECIST 1.1 and irRECIST. Objective: To assess duration of response (DOR) by RECIST 1.1. Objective: To assess overall survival (OS) in this population. Objective: To assess safety and tolerability.